Lupin receives USFDA approval for generic Benicar Tablets

28 Apr 2017 Evaluate

Lupin has received final approval for its Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg from the United States Food and Drug Administration (USFDA) to market generic version of Benicar tablets, 5 mg, 20 mg and 40 mg. Benicar tablets had US sales of $1,036 million, as per IMS MAT December 2016.

Lupin's Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg are the AB rated generic equivalent of Daiichi Sankyo Inc.'s Benicar tablets. It is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure.

Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.

Lupin Share Price

2149.65 -15.40 (-0.71%)
23-Jan-2026 11:15 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1630.70
Dr. Reddys Lab 1243.65
Cipla 1380.55
Zydus Lifesciences 888.45
Lupin 2149.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×